上海
*僅供醫(yī)學(xué)專業(yè)人士閱讀參考
埃萬妥單抗聯(lián)合方案在EGFR突變NSCLC伴腦轉(zhuǎn)移患者的一線與二線治療中均展現(xiàn)出卓越的顱內(nèi)病灶控制能力和生存獲益，開啟了精準(zhǔn)、全程管理的新時代。
*以下內(nèi)容僅供醫(yī)療衛(wèi)生專業(yè)人士瀏覽。
參考文獻(xiàn)：
[1]中國抗癌協(xié)會腫瘤病理專業(yè)委員會分子病理協(xié)作組, 中國醫(yī)師協(xié)會腫瘤多學(xué)科診療專業(yè)委員會. 非小細(xì)胞肺癌表皮生長因子受體20號外顯子插入突變檢測臨床實(shí)踐中國專家共識（2024版）[J]. 中華腫瘤雜志, 2024, 46(3):179-188.
[2]趙軍, 等. 中國驅(qū)動基因陽性非小細(xì)胞肺癌腦轉(zhuǎn)移臨床診療指南(2025版)[J].中國肺癌雜志, 2025(1).
[3]Shirish MG, et al. Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study. 2024 WCLC. OA.02.03.
[4]Yang JC, et al. MARIPOSA Investigators. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025 Sep 7.
[5]Zhou C, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051.
[6]Chouaid C, et al. Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study. Lung Cancer. 2025 May;203:108548.
[7]Passaro A, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024 Jan;35(1):77-90.
[8]Shih J, et al. Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis. 2023 ESMO Asia. LBA11.
[9]NCCN Guidelines Central Nervous System Cancers. Version 2.2025.
審批編碼：CP-552514
批準(zhǔn)分發(fā)日期：11/17/2025
有效期：11/17/2026
*此文僅用于向醫(yī)療衛(wèi)生專業(yè)人士提供科學(xué)信息，不代表平臺立場。
特別聲明：以上內(nèi)容(如有圖片或視頻亦包括在內(nèi))為自媒體平臺“網(wǎng)易號”用戶上傳并發(fā)布，本平臺僅提供信息存儲服務(wù)。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
冷桂零落
